ENTWICKLUNGEN IN DER THERAPIE DES FORTGESCHRITTENEN OVARIALKARZINOMS FIGO III

Translated title of the contribution: Development in the therapy of the advanced ovarian cancer FIGO III

W. Kuhn, F. Janicke, L. Pache, M. Holscher, G. Schattenmann, B. Schmalfeldt, H. Anderl, G. Schule, P. Dettmar, J. R. Siewert, H. Graeff

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated. In 38% of the patients there was no residual tumour postoperatively, in 40.8% the residual tumor was smaller than 2 cm. In 51.5% bowel resections were necessary, a stoma was unavoidable in just one case. A lymphadenectomy (pelvic, paraaortic or combined) was done in 46.6% of the patients. Postoperatively, 54.4% of the patients received a platinum-based chemotherapy, in the other patients other kinds of chemotherapy were applied. A radiation of the whole abdomen was done only in 3.9%. A median survival time for more than 60 months could be achieved in tumour-free patients due to the increased radical operations in combination with the platinum based chemotherapy. The lymphadenectomy seems to prolong the survival time of the patients. The positive nodal status is definitely unfavourable for the prognosis. By this therapeutic approach, an increased survival time with a good life quality can be achieved.

Translated title of the contributionDevelopment in the therapy of the advanced ovarian cancer FIGO III
Original languageGerman
Pages (from-to)293-302
Number of pages10
JournalGeburtshilfe und Frauenheilkunde
Volume53
Issue number5
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Development in the therapy of the advanced ovarian cancer FIGO III'. Together they form a unique fingerprint.

Cite this